Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01428973
Other study ID # TJB1016P1
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date September 2011
Est. completion date December 2024

Study information

Verified date May 2024
Source University of Liege
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The present project is a multicenter phase II trail aiming at comparing which of the two postgrafting immunosuppressive regimens proposed in this study will be best suited to prevent graft-versus-host disease (GVDH). The immunosuppressive regimens will consist of: Tacrolimus plus Mycophenolate Mofetil or Tacrolimus plus Sirolimus. Before grafting patients will undergo a reduced-intensity conditioning with Fludarabine/total body irradiation (TBI) or Fludarabine/Busulfan/anti-thymoglobuline. Following the interim analysis of October 2014, the protocol has been amended to allow inclusion only after Flu-TBI conditioning. The hypothesis is that the Tacrolimus plus Sirolimus regimen will be associated with better progression-free survival due to a lower incidence of relapse/progression.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 200
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 16 Years to 75 Years
Eligibility Inclusion Criteria: 1. Hematological malignancies confirmed histologically and not rapidly progressing: - Acute myeloid leukemia (AML) in complete remission (CR) (defined as = 5% marrow blasts and absence of blasts in the peripheral blood); - Myelodysplastic syndromes (MDS) with = 5% marrow blasts and absence of blasts in the peripheral blood; - Chronic myeloid leukemia (CML) in chronic phase (CP); - Myeloproliferative neoplasms not in blast crisis and not with extensive marrow fibrosis; - Acute lymphoid leukemia (ALL)in CR; - Multiple myeloma not rapidly progressing; - chronic lymphocytic leukemia (CLL); - Non-Hodgkin's lymphoma (aggressive NHL should have chemosensitive disease); - Hodgkin's disease with chemosensitive disease; 2. 10/10 HLA-A, -B, -C, DRB1 and DQBI allele-matched donor fit to/willing to donate PBSC. 3. Clinical situations: 1. Theoretical indication for a standard allotransplant, but not feasible because: - Age > 50 yrs; - Unacceptable end organ performance; - At the physician's decision; - Patient's refusal. 2. Indication for a standard auto-transplant: perform mini-allotransplantation 2-6 months after standard autotransplant. 4. Other inclusion criteria: - Male or female; fertile patients must use a reliable contraception method; - Age = 75 yrs (children of any age are allowed in the protocol); - Informed consent given by patient or his/her guardian if of minor age. Exclusion Criteria: - Any condition not fulfilling inclusion criteria; - HIV positive; - Non-hematological malignancy(ies) (except non-melanoma skin cancer) < 3 years before nonmyeloablative hematopoietic cell transplantation (HCT); - Life expectancy severely limited by disease other than malignancy; - Administration of cytotoxic agent(s) for "cytoreduction" within three weeks prior to initiating the nonmyeloablative transplant conditioning (Exceptions are hydroxyurea and imatinib mesylate); - CNS involvement with disease refractory to intrathecal chemotherapy; - Terminal organ failure, except for renal failure (dialysis acceptable) 1. Cardiac: Symptomatic coronary artery disease or other cardiac failure requiring therapy; ejection fraction <35%; uncontrolled arrhythmia, uncontrolled hypertension; 2. Pulmonary: DLCO < 35% and/or receiving supplementary continuous oxygen; 3. Hepatic: Fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evinced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin >3 mg/dL, and symptomatic biliary disease; - Uncontrolled infection; - Karnofsky Performance Score <70%; - Patient is a fertile man or woman who is unwilling to use contraceptive techniques during and for 12 months following treatment; - Patient is a female who is pregnant or breastfeeding; - Any condition precluding the use of sirolimus or MMF; - One HLA mismatch with peripheral blood stem cells (PBSC) fit to/willing to donate.

Study Design


Intervention

Drug:
Mycophenolate mofetil
Tablets. For HLA-identical sibling donors:15 mg/kg t.i.d from day 0 to day 28. For alternative donor: 15 mg/kg, from day 0 to day 42.
Sirolimus
Tablets. 6 mg loading dose on day -3, followed by (1)-2 mg daily to a target trough level of 5 to 10 ng/mL. Full doses will be given until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses will then be progressively tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD.

Locations

Country Name City State
Belgium Ziekenhuis Netwerk Antwerpen (ZNA) Antwerpen, Antwerpen
Belgium AZ Sint-Jan AV Brugge West Flanders
Belgium AZ VUB Jette Brussels Brussels Region Capital
Belgium Jules Bordet Institute Brussels Brabant
Belgium Queen Fabiola Children's University Hospital Brussels Brussels, Region Capital
Belgium Cliniques universitaires Saint-Luc- Université Catholique de Louvain Brussels, Brussels Region Capital
Belgium University Hospital, Antwerp Edegem Antwerp
Belgium UZ Gent Gent Flanders Ost
Belgium Jolimont Hospital Haine Saint Paul Haine St-Paul Hainaut
Belgium University Hospital, Gasthuisberg Leuven Flamish Brabant
Belgium CHU Sart Tilman Liège
Belgium H.-Hart Hospital Roeselare-Menen Roeselare Western Flanders
Belgium Cliniques Universitaires de Mont-Godinne Yvoir Namur

Sponsors (12)

Lead Sponsor Collaborator
University of Liege AZ Delta, AZ Sint-Jan AV, AZ-VUB, Cliniques Universitaires de Mont-Godinne, Cliniques universitaires Saint-Luc- Université Catholique de Louvain, Hospital de Jolimont, Jules Bordet Institute, University Hospital, Antwerp, University Hospital, Gasthuisberg, University Hospital, Ghent, Ziekenhuis Netwerk Antwerpen (ZNA)

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free survival To compare the 1-year progression-free survival between the 2 prophylactic arms (Tracolimus/Mycophenolate Mofetil and Tracolimus/Sirolimus) in the whole group of patients and separately in those conditioned with Fluradabine/TBI or Fluradabine plus Busulfan and anti-thymocyte globulin. 1 year after transplantation
Secondary Relapse rate; nonrelapse mortality and overall survival To compare relapse rate, nonrelapse mortality, and overall survival in the 2 prophyltic arms (Tracolimus/Mycophenolate Mofetil and Tracolimus/Sirolimus) 1, 2 and 5 years after hematopietic stem cell transplantation (HSCT) in the whole group of patients and separately in those conditioned with Fluradabine/TBI or Fluradabine plus Busulfan and anti-thymocyte globulin. 1, 2 and 5 years after transplantation
Secondary Progression free survival To compare progression-free survival in the 2 phrophylactic arms (Tracolimus/Mycophenolate Mofetil and Tracolimus/Sirolimus) 2 and 5 years after HSCT, in the whole group of patients and separately in those conditioned with Fluradabine/TBI or Fluradabine plus Busulfan and anti-thymocyte globulin. 2 and 5 years after transplantation
Secondary Engraftment To compare hematopoietic (whole blood and T cell chimerism) engraftment and to evaluate the 1-year incidence of graft rejection in the 2 prophylctic arms (Tracolimus/Mycophenolate Mofetil and Tracolimus/Sirolimus), in the whole group of patients and separately in those conditioned with Fluradabine/TBI or Fluradabine plus Busulfan and anti-thymocyte globulin. 1 year after transplantation
Secondary Acute GVDH To compare the 6-mo incidence of grades II-IV and III-IV acute GVHD in the 2 prophylactic arms (Tracolimus/Mycophenolate Mofetil and Tracolimus/Sirolimus), in the whole group of patients and separately in those conditioned with Fluradabine/TBI or Fluradabine plus Busulfan and anti-thymocyte globulin. 6 months after transplantation
Secondary Chronic GVDH To compare the 1-yr incidence of chronic GVHD in the phrophylactic 2 prophylactic arms (Tracolimus/Mycophenolate Mofetil and Tracolimus/Sirolimus), in the whole group of patients and separately in those conditioned with Fluradabine/TBI or Fluradabine plus Busulfan and anti-thymocyte globulin. 1 year after transplantation
Secondary Immunological reconstitution To compare the quality and timing of immunologic reconstitution in the 2 prophylactic arms (Tracolimus/Mycophenolate Mofetil and Tracolimus/Sirolimus),in the whole group of patients and separately in those conditioned with Fluradabine/TBI or Fluradabine plus Busulfan and anti-thymocyte globulin. 3 mo, 6 mo, 1 yr, 2 yrs and 5 yrs after transplantation
Secondary Infection To compare the 1-yr incidences of bacterial, fungal and viral infections in the 2 prophylactic arms (Tracolimus/Mycophenolate Mofetil and Tracolimus/Sirolimus), in the whole group of patients and separately in those conditioned with Fluradabine/TBI or Fluradabine plus Busulfan and anti-thymocyte globulin. 1 year after transplantation
See also
  Status Clinical Trial Phase
Terminated NCT03248479 - Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies Phase 1
Recruiting NCT05454241 - CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies Phase 2
Recruiting NCT06041815 - Correlation Between Gut Microbiota and Clinical Response to CAR-T Treatment for Hematological Malignancies
Active, not recruiting NCT05005442 - A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004) Phase 2
Recruiting NCT02300571 - Observational Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant N/A
Completed NCT00379587 - Rituximab for Prevention of Chronic GVHD Phase 1/Phase 2
Completed NCT01162096 - Reduced Intensity Haploidentical Transplant for Hematological Malignancies Phase 1/Phase 2
Terminated NCT00506948 - Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD) Phase 2
Active, not recruiting NCT04557098 - A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma Phase 2
Recruiting NCT04283097 - Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects Phase 1
Completed NCT03067155 - CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation. Phase 2
Completed NCT01725555 - A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors Phase 1
Completed NCT00438178 - Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies Phase 1
Completed NCT03711604 - Compassionate Use Study of Tenalisib (RP6530) Phase 1/Phase 2
Withdrawn NCT01168882 - Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies Phase 1
Completed NCT01246206 - Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT Phase 2
Completed NCT01172132 - The Use of Intensive Care in Critically Ill Cancer Haematological Patients: "TRIAL-OH" N/A
Completed NCT00506402 - A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies Phase 1
Active, not recruiting NCT00163644 - RCT to Investigate Whether an Exercise Programme Improves the Physical Performance and QOL After BMT N/A
Completed NCT01063647 - Dose-range Finding Treosulfan-based Conditioning Phase 1/Phase 2